Low-Dose Interleukin-2 and Pembrolizumab for the Treatment of Stage IV Non-Small Cell Lung Cancer

Clinical trial NCT05493566 · RECRUITING

Trial details

NCT number: NCT05493566
Sponsor: Emory University
Status: RECRUITING
Phase: Early Phase 1
Study type: INTERVENTIONAL

Lung Non-Small Cell Carcinoma Stage IV Lung Cancer AJCC v8 Stage IVA Lung Cancer AJCC v8 Stage IVB Lung Cancer AJCC v8

Start date: 2022-11-01
Primary completion: 2027-01-07
Enrollment: 15

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.